Such mutations in ATP13A2, also named PARK9, were first identified in 2006 in a Chilean family and are associated with a juvenile-onset, levodopa-responsive type of Parkinsonism called Kufor-Rakeb syndrome (KRS). This evidence concerns the gene ATP13A2 and parkinsonism due to ATP13A2 deficiency.